
<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/joey/Project/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.4.2-SNAPSHOT" ident="GROBID" when="2017-08-10T23:59+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Combenefit: an interactive platform for the analysis and visualization of drug combinations</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName>
								<forename type="first">Giovanni</forename>
								<forename type="middle">Y</forename>
								<surname>Di Veroli</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CRUK Cambridge Institute</orgName>
								<orgName type="institution" key="instit2">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Early Clinical Development</orgName>
								<orgName type="laboratory">Innovative Medicines and Early Development Biotech Unit</orgName>
								<orgName type="institution">AstraZeneca</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Chiara</forename>
								<surname>Fornari</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CRUK Cambridge Institute</orgName>
								<orgName type="institution" key="instit2">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Dennis</forename>
								<surname>Wang</surname>
							</persName>
							<affiliation key="aff2">
								<orgName type="department">Oncology Innovative Medicines</orgName>
								<orgName type="institution">AstraZeneca</orgName>
								<address>
									<settlement>Bioinformatics, Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Sé</forename>
								<forename type="middle">Verine</forename>
								<surname>Mollard</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CRUK Cambridge Institute</orgName>
								<orgName type="institution" key="instit2">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Jo</forename>
								<forename type="middle">L</forename>
								<surname>Bramhall</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CRUK Cambridge Institute</orgName>
								<orgName type="institution" key="instit2">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Frances</forename>
								<forename type="middle">M</forename>
								<surname>Richards</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CRUK Cambridge Institute</orgName>
								<orgName type="institution" key="instit2">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Duncan</forename>
								<forename type="middle">I</forename>
								<surname>Jodrell</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="institution" key="instit1">CRUK Cambridge Institute</orgName>
								<orgName type="institution" key="instit2">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Combenefit: an interactive platform for the analysis and visualization of drug combinations</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1093/bioinformatics/btw230</idno>
					<note type="submission">Received on December 14, 2015; revised on April 5, 2016; accepted on April 20, 2016</note>
					<note>Systems biology *To whom correspondence should be addressed Associate Editor: Jonathan Wren Contact: Giovanni.DiVeroli@cruk.cam.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract>
				<p>Motivation: Many drug combinations are routinely assessed to identify synergistic interactions in the attempt to develop novel treatment strategies. Appropriate software is required to analyze the results of these studies. Results: We present Combenefit, new free software tool that enables the visualization, analysis and quantification of drug combination effects in terms of synergy and/or antagonism. Data from combinations assays can be processed using classical Synergy models (Loewe, Bliss, HSA), as single experiments or in batch for High Throughput Screens. This user-friendly tool provides laboratory scientists with an easy and systematic way to analyze their data. The companion package provides bioinformaticians with critical implementations of routines enabling the processing of combination data. Availability and Implementation: Combenefit is provided as a Matlab package but also as stand-alone software for Windows (http://sourceforge.net/projects/combenefit/).</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p>The combination of drugs is an important strategy to treat various diseases. The goal is to increase efficacy and, through the avoidance of overlapping toxicity, improve the therapeutic index of treatment (<ref type="bibr" target="#b9">Long et al., 2014</ref>). At the discovery stage, research often focuses on the identification of synergistic target effects using in vitro systems (<ref type="bibr" target="#b6">Leh ar et al., 2009;</ref><ref type="bibr" target="#b13">Roemer and Boone, 2013;</ref><ref type="bibr" target="#b14">Sun et al., 2013</ref>). Large scale combination screens testing multiple pairwise combinations of drugs across different concentration ranges and cell lines are being performed with increasing frequency (<ref type="bibr" target="#b4">He et al., 2015;</ref><ref type="bibr" target="#b5">Held et al., 2013;</ref><ref type="bibr" target="#b10">Mathews Griner et al., 2014</ref>). Typically, the dose–response data generated during these experiments are then analyzed in terms of synergistic or antagonistic effects. Free software were developed in the past but these are limited in terms of data handling and available options, particularly given high throughput screens (HTS) requirements (http://www.combosyn.com/;<ref type="bibr" target="#b2">Dressler et al., 1999;</ref><ref type="bibr" target="#b12">Prichard and Shipman, 1990</ref>). Two recent commercial software packages offer advanced features such as automated analyses, choice from a variety of models, quality curve-fitting, variety of graphical displays and metrics quantification (Chalice http://cwr.horizondiscovery.com; Genedata https://www.genedata.com). There is a lack of free, advanced, scalable, software for the analysis of drug combinations. As part of the growing effort in the search of effective combinations, we present here Combenefit ('Combinations Benefit'), a new software tool that enables the visualization, analysis and quantification of drug combination effects, in terms of synergy and/or antagonism, for single combination experiments but also HTS as per commercial packages (<ref type="figure">Table 1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">General overview</head><p>Combenefit implements a surface approach, where in vitro experimental data is compared to mathematical models of dose–responses for non-synergistic combinations (also termed additive or independent combinations;<ref type="bibr" target="#b3">Greco and Bravo, 1995</ref>). The three classical models, namely the Loewe (<ref type="bibr" target="#b8">Loewe and Muchnick, 1926;</ref><ref type="bibr" target="#b7">Loewe, 1953</ref>), the Bliss (<ref type="bibr" target="#b0">Bliss, 1939;</ref><ref type="bibr" target="#b16">Webb, 1963</ref>) and the Highest Single Agent (HSA;<ref type="bibr" target="#b10">Mathews Griner et al., 2014;</ref><ref type="bibr" target="#b15">Tan et al., 2012</ref>) models have been incorporated. These models have been used extensively in the literature, with different fields having their preference and sometimes alternative names for these same models (<ref type="bibr" target="#b3">Greco and Bravo, 1995;</ref><ref type="bibr" target="#b11">Odds, 2003</ref>). It is important to use these models in a consistent way and to provide results in the context of the model used. Additionally, our own group is currently developing a new general model which, together with any other future feature, will be incorporated into Combenefit. The approach implemented in Combenefit can be summarized as follows (<ref type="figure" target="#fig_0">Fig. 1a</ref>). The experimental dose–response surface that delineates combination effects in concentration space, is first read by the software as a matrix of % of the control value across concentrations. Single agent effects are extracted from this data and fitted with a dose response curve. Based on the two single agent dose response curves, a model-based combination dose–response surface is derived. This surface provides a 'reference' dose–response surface for a non-synergistic (additive/independent) combination, whose characteristics are determined by the selected model (Loewe, Bliss, etc.). The experimental combination dose response surface is then compared to the model-generated one, resulting in a synergy distribution in concentration space. This synergy distribution can be further summarized via various metrics as described below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Using Combenefit</head><p>The software is available as a standalone application for Windows or as a Matlab package. The standalone application can be installed automatically and is then directly accessed through its own icon. The Matlab package needs to be saved in a dedicated folder which is then accessed via Matlab by calling the Combenefit routine contained in the package. Laboratory scientists can quickly and easily analyze their data using either version. Bioinformaticians can use the code provided in the Matlab package to facilitate their own projects involving drugs combinations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Typical analysis</head><p>A typical analysis is performed as follows. Upon completion of experiments, the results of a specific combination (including replicates if available) are saved in .xls files (the data is ordered with the first drug in columns and the second in rows; a template is provided). Once Combenefit is launched, the project folder containing all experimental .xls files is selected (<ref type="figure" target="#fig_0">Fig. 1b</ref>). Then, one or more reference models can be selected. Other options and graphical outputs can be chosen as per requirements/preferences. The graphical outputs consist of: (i) the single agent dose response data and its fitting, (ii) the combination dose response (Four different displays), (iii) the modelgenerated reference combination dose response, i.e. the prediction of effect if the drugs are not synergistic (Three different displays) and</p><p>(iv) the resulting synergy distribution (Three different displays). Additionally, a fourth graphic mapping the synergy distribution onto the dose–response surface can also be displayed to facilitate<ref type="figure">Table 1</ref>. Features of available software for drugs combinations analyses. L: Loewe, B: Bliss, H: HSA, DR: Dose–response curve, M: Matrix view, C: contours, S: surfaces, I: Isobolograms, SM: synergy mapped to dose–response surfaces, F: Fa related curves, see (<ref type="bibr" target="#b1">Chou, 2010</ref>). Note: we have not included CombiTool (<ref type="bibr" target="#b2">Dressler et al., 1999</ref>) because it does not appear to be available anymore</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Metrics and batch analysis</head><p>The analyses described above result in a synergy distribution for the combination being processed. To facilitate comparison across experiments, or for HTS applications, it is useful to summarize the resulting synergy and/or antagonism distribution using one or more metrics. Combenefit provides a set of metrics (or scores) which captures information about the synergy distribution. These include metrics such as the maximum synergy, the integrated and the weighted integrated synergy and concentration value at which synergy is most dense (for a full list of metrics and their formulation, please see the Supplementary Material). During HTS, large volumes of combinations and cell lines are investigated using automated technology. Combenefit can be used to analyze the large amount of data derived with these screens. Using Combenefit, the user selects the folder containing all experiments (each in an individual sub-folder) and then selects the 'Batch Analysis' option. Upon running the analysis, Combenefit will batch process in a sequential way all the folders. The results of the analysis are summarized in a table containing all the experiments in rows and the metrics in columns. Typically, the highest hits are then visually inspected using Combenefit's graphical outputs to improve understanding of the data and prioritize drug combinations. Combenefit has been recently used to generate the AstraZeneca dataset (11 500 combinations) provided for the current AstraZeneca-Sanger Drug Combination Prediction DREAM challenge (http://dreamchallenges.org/). In summary, we have described the overall implementation and functioning of Combenefit, new software which offers advanced graphical capabilities and allows for model-based quantification of drug combinations in single and high-throughput settings. We hope that this new tool will continue to improve and will help many scientists in a variety of fields involving combination data analyses.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig.1.</head><figDesc>Fig. 1. Analysis and visualization of drug combinations with Combenefit. (a) Illustration of analysis principle. (b) Illustration of automated processing</figDesc></figure>

			<note place="foot">G.Y.Di Veroli et al. at :: on August 30, 2016 http://bioinformatics.oxfordjournals.org/ Downloaded from</note>

			<note place="foot">at :: on August 30, 2016 http://bioinformatics.oxfordjournals.org/ Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>We acknowledge all support and feedback from Combenefit users.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>This work has been supported by the Cancer Research UK grant C14303/ A17197. Conflict of Interest: none declared.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct   xml:id="b0">
	<analytic>
		<title level="a" type="main">The toxicity of poisons applied jointly</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<forename type="middle">I</forename>
				<surname>Bliss</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann. Appl. Biol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="585" to="615" />
			<date type="published" when="1939" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b1">
	<analytic>
		<title level="a" type="main">Drug combination studies and their synergy quantification using the Chou–Talalay method</title>
		<author>
			<persName>
				<forename type="first">T</forename>
				<forename type="middle">C</forename>
				<surname>Chou</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="440" to="446" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b2">
	<analytic>
		<title level="a" type="main">CombiTool–a new computer program for analyzing combination experiments with biologically active agents</title>
		<author>
			<persName>
				<forename type="first">V</forename>
				<surname>Dressler</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comput. Biomed. Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="145" to="160" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b3">
	<analytic>
		<title level="a" type="main">The search for synergy: a critical review from a response surface perspective</title>
		<author>
			<persName>
				<forename type="first">W</forename>
				<forename type="middle">R</forename>
				<surname>Greco</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">G</forename>
				<surname>Bravo</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">P</forename>
				<forename type="middle">J C</forename>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol. Rev</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="331" to="385" />
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b4">
	<analytic>
		<title level="a" type="main">Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>He</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b5">
	<analytic>
		<title level="a" type="main">Genotype-selective combination therapies for melanoma identified by high-throughput drug screening</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">A</forename>
				<surname>Held</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="52" to="67" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b6">
	<analytic>
		<title level="a" type="main">Synergistic drug combinations tend to improve therapeutically relevant selectivity</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Leh Ar</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="659" to="666" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b7">
	<analytic>
		<title level="a" type="main">The problem of synergism and antagonism of combined drugs</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Loewe</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">ArzneimiettelForschung</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="286" to="290" />
			<date type="published" when="1953" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b8">
	<analytic>
		<title level="a" type="main">Effect of combinations: mathematical basis of problem</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Loewe</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Muchnick</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch. Exp. Pathol. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="313" to="326" />
			<date type="published" when="1926" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b9">
	<analytic>
		<title level="a" type="main">Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma</title>
		<author>
			<persName>
				<forename type="first">G</forename>
				<forename type="middle">V</forename>
				<surname>Long</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">5694</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b10">
	<analytic>
		<title level="a" type="main">High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells</title>
		<author>
			<persName>
				<forename type="first">Mathews</forename>
				<surname>Griner</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">L</forename>
				<forename type="middle">A</forename>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proc. Natl. Acad. Sci. USA</title>
		<meeting>. Natl. Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="2014" />
			<biblScope unit="page" from="2349" to="2354" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b11">
	<analytic>
		<title level="a" type="main">Synergy, antagonism, and what the chequerboard puts between them</title>
		<author>
			<persName>
				<forename type="first">F</forename>
				<forename type="middle">C</forename>
				<surname>Odds</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Antimicrob. Chemother</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b12">
	<analytic>
		<title level="a" type="main">A three-dimensional model to analyze drug-drug interactions</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">N</forename>
				<surname>Prichard</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Shipman</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antiviral Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="181" to="205" />
			<date type="published" when="1990" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b13">
	<analytic>
		<title level="a" type="main">Systems-level antimicrobial drug and drug synergy discovery</title>
		<author>
			<persName>
				<forename type="first">T</forename>
				<surname>Roemer</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Boone</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="222" to="231" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b14">
	<analytic>
		<title level="a" type="main">High-throughput methods for combinatorial drug discovery</title>
		<author>
			<persName>
				<forename type="first">X</forename>
				<surname>Sun</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Trans. Med</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="205" to="206" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b15">
	<analytic>
		<title level="a" type="main">Systematic identification of synergistic drug pairs targeting HIV</title>
		<author>
			<persName>
				<forename type="first">X</forename>
				<surname>Tan</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1125" to="1130" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b16">
	<analytic>
		<title level="a" type="main">Effect of more than one inhibitor</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">L</forename>
				<surname>Webb</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Enzyme Metab. Inhib</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="66" to="79" />
			<date type="published" when="1963" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b17">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Combenefit</title>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>